<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-656
Date of Submission: 2024-09-08

This report was submitted by a Physician from Monroe PLC Medical Center concerning patient ANON-PX-1037. The subject is a 46-year-old male with a significant medical history including osteoarthritis, atrial fibrillation, type 2 diabetes, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intravenous route at a dosage of 36mg, initiated on 2024-06-11 for Pain and inflammation with the course ongoing.

On approximately 2024-07-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Headache, Pruritus. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed every and advised product. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Seat course few change.</data>
report_id: ADR-2024-656
report_date: '2024-09-08'
patient_details:
  patient_id: ANON-PX-1037
  gender: Male
  relevant_history:
  - osteoarthritis
  - atrial fibrillation
  - type 2 diabetes
  - migraines
  age_at_reaction: 46
suspected_drugs:
- drug_name: Ibuprofen
  dosage: 36mg
  route_of_administration: Intravenous
  start_date: '2024-06-11'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2024-07-18'
  severity: Moderate
  outcome: Unknown
  intervention_required: false
- symptom_name: Headache
  onset_date: '2024-07-18'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed every and advised product.
- symptom_name: Pruritus
  onset_date: '2024-07-18'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
reporting_facility: Monroe PLC Medical Center
reporter_type: Physician
notes: Seat course few change.
